Mirzotamab, an IgG1kappa antibody, targets CD276/B7-H3 and conjugates with Clezutoclax, a BCL-2 inhibitor, to create Mirzotamab clezutoclax. This antibody-drug conjugate (ADC), identified as ABBV-155, is currently under investigation in conjunction with taxa
CAS Nummer:
[2229859-11-2]
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten